Fox Chase Cancer Center

Fox Chase Cancer Center's mission is to reduce the burden of human cancer. Fox Chase's activities include basic, clinical and prevention research; detection and Fox Chase Cancer Centertreatment of cancer; and community outreach programs.

 

Fox Chase Cancer Center is an independent, nonprofit institution formed in 1974 by the union of American Oncologic Hospital (the nation's first cancer hospital, established in 1904) and the Institute for Cancer Research (founded in 1927).

 

Fox Chase's 100-bed hospital is one of the few facilities in the country devoted entirely to cancer care. About 170 clinical trials of new prevention, diagnostic and treatment techniques are under way at any one time. Fox Chase is also involved in developing trials to test new agents that may prevent cancer in high-risk individuals. Combining research in many disciplines with patient care enables Fox Chase to translate new research findings into medical applications that may become models for improved cancer care.

 

Fox Chase is structured around three divisions: medical science, basic science and population science.

 
Medical science is committed to providing excellent patient care and conducting a broad-based program of clinical research, including clinical trials.
The division of basic science is renowned worldwide for its work in understanding both normal and abnormal cell growth and development.

The goal of the division of population science is to identify people at high risk of cancer and to develop strategies to reduce these risks through programs of prevention and early detection.

 
Fox Chase has 70 robust basic science programs ranging from labs focusing on the most fundamental cellular problems to translational research. These programs are complemented with superior core facilities allowing researchers to spend less time on repetitive tasks, and more time designing and completing experiments. Our programs include:

 

Biomolecular Structure & Function
Breast Cancer
Cancer Prevention & Control
Cellular & Developmental
Biology Developmental Therapeutics
Human Genetics
Immunobiology
Ovarian Cancer Prostate Cancer
Tumor Cell Biology
Viral Pathogenesis

 

Institutional Contacts 

Patricia Weeks

Business Development 

Email 

 Sandra Weckesser, J.D.

Institutional Advancement  

 

 For more information, visit our website at www.fccc.edu. 

 

Timothy J. Yen, Ph.D.
Genome Stability Working Group Leader
Senior Member — Basic Science Division

Email 

  

Yishihiro Matsumoto, Ph.D.
Member — Basic Science Division
Email  
Louis M. Weiner, M.D.
Chairman, Medical Oncology
Vice President, Translational Research
Senior Member — Medical Science Division
Developmental Therapeutics Group Leader

Email  

 

Hong Yan, Ph.D.
Member — Basic Science Division
Email 
Anna Skalka, Ph.D.
Senior Vice President, Basic Science Division
Senior Member — Basic Science Division

Email 

 

Peter D. Adams, Ph.D.
Member — Basic Science Division
Email  
Alfonso Bellacosa, M.D., Ph.D.
Member — Population Science Division

Email 

 

Margret Einarson, Ph.D.
Translational Facility Manager
Email 
Dominique Broccoli, Ph.D.
Member — Basic Science Division
Email